8-K: Connect Biopharma Receives Positive FDA Feedback, Plans Phase 2 Trials for Rademikibart in Asthma and COPD

Connect Biopharma announced positive feedback from the FDA regarding its plan to initiate parallel Phase 2 trials of rademikibart for patients with moderate-to-severe asthma or COPD experiencing acute exacerbations.

Summary

• Connect Biopharma received positive feedback from the FDA on its plan to initiate Phase 2 trials for rademikibart.
• The trials will focus on patients with moderate-to-severe asthma or COPD experiencing acute exacerbations.
• Two parallel, randomized, double-blind, placebo-controlled trials are planned, each enrolling approximately 160 patients.
• The trials will evaluate a single 600 mg subcutaneous dose of rademikibart over 28 days following an acute exacerbation.
• Data from both Phase 2 trials are expected in the first half of 2026.
• The company believes rademikibart could provide rapid benefit to patients seen in emergency departments or hospitalized due to exacerbations.
• The company's cash runway extends into 2027.

Sentiment

Score: 7

Explanation: The document conveys a positive sentiment due to the positive feedback from the FDA and the planned Phase 2 trials. However, it also acknowledges the risks and uncertainties inherent in drug development.

Positives

• Positive feedback from the FDA on the Phase 2 trial design.
• Rademikibart has shown promising data in a previous Phase 2 study for asthma maintenance treatment.
• The trials address an unmet need for treatments following acute exacerbations of asthma and COPD.
• The company has a cash runway into 2027.

Risks

• The success of clinical trials is not guaranteed.
• Drug development and commercialization involve a high degree of risk.
• Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval.
• Unexpected safety or efficacy data or results observed during clinical trials or in data readouts could impact the program.
• Delays in or disruptions to the Company's business or clinical trials due to geopolitical changes or other external factors could impact the program.

Future Outlook

The company plans to begin enrolling patients in parallel Phase 2 trials of rademikibart in patients with moderate-to-severe asthma or COPD experiencing an acute exacerbation during the second quarter of 2025, and expects to report data from both trials in the first half of 2026.

Management Comments

• Barry Quart, Pharm.D., CEO and Director of Connect Biopharma, stated that they are pleased to have the FDA's alignment on their two parallel Phase 2 trials evaluating rademikibart in patients experiencing an acute exacerbation of asthma or COPD.
• Mario Castro, MD, MPH, Professor and Chief of Pulmonary, Critical Care and Sleep Medicine at the University of Kansas School of Medicine, stated that the pulmonology community is encouraged by the plan to evaluate the potential benefits of a single 600 mg SC dose of rademikibart following an acute exacerbation in these Phase 2 trials in patients with asthma and COPD.

Industry Context

The announcement highlights the unmet need for biologic therapies to address airway symptoms immediately after an acute exacerbation of asthma and COPD, as current biologics are primarily used for maintenance therapy. Connect Biopharma is positioning rademikibart as a potential solution to this gap in treatment.

Comparison to Industry Standards

• The document references a study (Ramakrishnan S, et.al. Lancet 2025; 13(1): 59-68) showing that approximately 45% of patients receiving the current standard of care experienced treatment failure in the 28 days following an acute exacerbation.
• This highlights the potential for rademikibart to improve outcomes compared to existing treatments.
• Companies like AstraZeneca (Symbicort, Pulmicort), GlaxoSmithKline (Advair, Breo), and Boehringer Ingelheim (Spiriva, Stiolto) offer maintenance therapies for asthma and COPD, but few address acute exacerbations directly with biologics.

Stakeholder Impact

• Positive results from the Phase 2 trials could benefit patients with asthma and COPD by providing a new treatment option for acute exacerbations.
• Successful development and commercialization of rademikibart could increase shareholder value.
• The trials may provide opportunities for medical professionals to participate in research and improve patient care.

Next Steps

• Initiate parallel Phase 2 trials of rademikibart in patients with moderate-to-severe asthma or COPD experiencing an acute exacerbation during the second quarter of 2025.
• Report data from both rademikibart Phase 2 trials in the first half of 2026.

Key Dates

Keywords

rademikibart, asthma, COPD, FDA, Phase 2 trials, exacerbation, biopharma